Related Experiment Video
Updated: Jun 6, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
Risk factors for death in children with visceral leishmaniasis
Márcia Jaqueline Alves de Queiroz Sampaio1, Nara Vasconcelos Cavalcanti, João Guilherme Bezerra Alves
1Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Insights
Identifying risk factors for death in children with visceral leishmaniasis (VL) is crucial for improving outcomes. Mucosal bleeding, jaundice, dyspnea, bacterial infections, low neutrophil counts, and low platelet counts predict mortality in pediatric VL patients.
Area of Science:
- Tropical Medicine
- Pediatric Infectious Diseases
- Epidemiology
Background:
- Visceral leishmaniasis (VL) poses a significant public health challenge in Latin America.
- Well-designed studies on diagnosis, treatment, and control of VL are limited.
- Few studies have focused on prognostic assessment in pediatric VL patients.
Purpose of the Study:
- To identify risk factors associated with mortality in children under 15 years old diagnosed with VL.
- To develop a prognostic score for predicting death in pediatric VL cases.
Main Methods:
- Retrospective cohort study of 546 pediatric patients with VL.
- Data collected from May 1996 to June 2006 at a referral center in northeast Brazil.
- Multivariate logistic regression analysis to identify independent predictors of mortality.
Main Results:
- The case-fatality rate for pediatric VL was 10% (57 deaths).
- Independent predictors of death included mucosal bleeding, jaundice, dyspnea, bacterial infections, neutrophil count <500/mm³, and platelet count <50,000/mm³.
- A proposed prognostic score demonstrated satisfactory sensitivity (88.7%) and specificity (78.5%).
Conclusions:
- Prognostic markers are vital for guiding clinical decisions regarding patient management and transfer.
- High-risk pediatric VL patients may benefit from early interventions like broad-spectrum antibiotics or blood product transfusions.
- Further clinical trials are needed to evaluate the efficacy of these baseline risk-based supportive interventions.
Background:
Despite the major public health importance of visceral leishmaniasis (VL) in Latin America, well-designed studies to inform diagnosis, treatment and control interventions are scarce. Few observational studies address prognostic assessment in patients with VL. This study aimed to identify risk factors for death in children aged less than 15 years admitted for VL treatment in a referral center in northeast Brazil.
Methodology/Principal Findings:
In a retrospective cohort, we reviewed 546 records of patients younger than 15 years admitted with the diagnosis of VL at the Instituto de Medicina Integral Professor Fernando Figueira between May 1996 and June 2006. Age ranged from 4 months to 13.7 years, and 275 (50%) were male. There were 57 deaths, with a case-fatality rate of 10%. In multivariate logistic regression, the independent predictors of risk of dying from VL were (adjusted OR, 95% CI): mucosal bleeding (4.1, 1.3-13.4), jaundice (4.4, 1.7-11.2), dyspnea (2.8, 1.2-6.1), suspected or confirmed bacterial infections (2.7, 1.2-6.1), neutrophil count <500/mm³ (3.1, 1.4-6.9) and platelet count <50,000/mm³ (11.7, 5.4-25.1). A prognostic score was proposed and had satisfactory sensitivity (88.7%) and specificity (78.5%).
Conclusions/Significance:
Prognostic and severity markers can be useful to inform clinical decisions such as whether a child with VL can be safely treated in the local healthcare facility or would potentially benefit from transfer to referral centers where advanced life support facilities are available. High risk patients may benefit from interventions such as early use of extended-spectrum antibiotics or transfusion of blood products. These baseline risk-based supportive interventions should be assessed in clinical trials.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents
Malaria
Drug Toxicity: Risk factors
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Amebiasis
